A Study On Biopharmaceutical Contract Manufacturing (BCMO) Market:
Biopharmaceutical products are pharmaceutical drugs that are synthesized, processed, or extracted from biological sources. Biopharmaceuticals include vaccines, blood products, recombinant therapeutic proteins, allergens, gene therapies, tissues and living cells used in cell therapy. Due to lack of manufacturing capabilities and to reduce the cost of manufacturing process, many companies are outsourcing. Contract manufacturing organizations offer a wide range of services such as cell line development, process optimization, fermentation biotechnology, analytical characterization, cGMP manufacturing, and validation in each stage of clinical development and commercialization.
Request Sample Report :https://precisionbusinessinsights.com/request-sample?product_id=15549
Biopharmaceutical contract manufacturing (BCMO) market is mainly driven by increase in investment of the pharma and biotechnological companies to develop and commercialize the biotechnological products. In addition, high revenue generation of blockbuster biological drugs such as humira, rituxan, lantus, avastin, herceptin and remicade are gaining traction from many biologics manufacturers. However, high cost associated with manufacture and stringent regulatory requirements are expected to hamper the growth of biologics contract manufacturing market.
The global biopharmaceutical contract manufacturing market is categorized into following:
1. Manufacturing process
• Mammalian Based
• Microbial Based
• Insect Based
• Plant Based
• Yeast Based
2. Type of service
• Fill and Finish services
• Cell Banking
• Analytical Services
• Process development
3. Molecule type
• Large Molecules
• Small Molecules
• Biopharmaceutical Companies
• Pharmaceutical Companies
• Research Organizations
And lastly, on the basis of geographical regions, the global biopharmaceutical contract manufacturing market have five major regions- North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America and Europe are front-runner in biopharmaceutical contract manufacturing (BCMO) market owing to increased approvals of biosimilars and increase in biopharmaceutical research organization. In Asia-Pacific region, emerging countries such as China and India are growing at a rapid rate owing to low cost of manufacturing.
Some of the key players in global biopharmaceutical contract manufacturing market are Lonza Group Ltd. (Switzerland), Boehringer Ingelheim GmbH (Germany), Charles River Laboratories, Inc. (U.S), Novartis AG (Switzerland) WuXi AppTec Group (China), Rentschler Biotechnologie GmbH (Germany), Fujifilm Holdings Corporation (Japan), Celonic AG (Switzerland), BIOMEVA GmbH (Germany), and ProBioGen AG (Germany) to name a few. In 2016, Moderna Therapeutics and Charles River Laboratories International, Inc., an early-stage contract research organization (CRO), had collaborated to support Moderna’s nonclinical discovery and development efforts.
In biopharmaceutical contract manufacturing market, the services providers are increasing their service offerings such as formulation, production and analytical services apart from conventional services. Cost considerations and quick services are expected continue to drive the outsourcing of biologics contract manufacturing market. In 2017, Lonza Group Ltd. acquired cell and gene contract manufacturer PharmaCell B.V., this acquisition broadens Lonza’s capabilities in Europe region. Companies expanding the manufacturing facilities to increase market share. For instance, in 2017, Boehringer Ingelheim GmbH started a new manufacturing facility in China to increase their manufacturing capacity.
For More Information : https://precisionbusinessinsights.com/market-reports/global-biopharmaceutical-contract-manufacturing-market/